(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) rose by a staggering 16.39% in 5 sessions from $6.03 at 16.39, to $7.02 at 11:57 EST on Friday, following the last session’s downward trend. NASDAQ is jumping 0.85% to $12,115.76, after two consecutive sessions in a row of gains.
Novavax’s last close was $6.59, 91.99% below its 52-week high of $82.30.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Yearly Top and Bottom Value
Novavax’s stock is valued at $7.02 at 11:57 EST, way under its 52-week high of $82.30 and way higher than its 52-week low of $5.61.
Novavax’s value is way below its 50-day moving average of $9.15 and way below its 200-day moving average of $25.74.
More news about Novavax (NVAX).